Table 3.
Subgroup analysis and sensitivity analysis for predictive accuracy of NLR for prediction of severity
| Categories | Sensitivity | Specificity | sAUC | DOR | I2(parameter) |
|---|---|---|---|---|---|
| Prediction of severity | |||||
| Less severity population (≤29%) N = 12 studies |
0.75 (0.66–0.82) | 0.76 (0.71–0.80) | 0.81 (0.80–0.84) | 9 (6–14) | 60.8% (Sen) 68.2% (Spe) |
| Higher severity population (>29%) N = 12 studies |
0.75 (0.68–0.81) | 0.73 (0.66–0.79) | 0.79 (0.75–0.82) | 2.8 (2.2–3.6) | 83.9% (Sen) 78.3% (Spe) |
| Proportion of hypertensive <25% N = 8 |
0.73 (0.65–0.80) | 0.78 (0.69–0.85) | 0.82 (0.78–0.85) | 10 (5–18) |
51.2% (Sen) 80.4% (Spe) |
| Proportion of hypertension 25% or more N = 9 |
0.77 (0.68–0.84) | 0.71 (0.67–0.75) | 0.85 (0.81–0.87) | 8 (6–12) | 86.1% (Sen) 48.2% (Spe) |
| Diabetes 15% or less N = 9 |
0.74 (0.64–0.82) | 0.79 (0.73–0.84) | 0.84 (0.80–0.87) | 11 (7–17) | 81.7% (Sen) 72.8% (Spe) |
| Diabetes 15% or more N = 8 |
0.76 (0.69–0.82) | 0.70 (0.65–0.73) | 0.76 (0.72–0.79) | 7 (5–11) | 69.1% (Sen) 43.8% (Spe) |
| CAD 10% or less N = 5 |
0.69 (0.56–0.80) | 0.79 (0.71–0.85) | 0.81 (0.78–0.85) | 8 (5–13) | 76.1% (Sen) 72.2% (Spe) |
| CAD 10% more N = 6 |
0.76 (0.72–0.80) | 0.77 (0.70–0.84) | 0.70 (0.66–0.74) | 8 (6–11) | 70.1% (Sen) 26.2% (Spe) |
| Male 55% or less N = −11 |
0.74 (0.64–0.82) | 0.75 (0.67–0.82) | 0.75 (0.71–0.79) | 9 (6–13) | 78.3% (Sen) 65.5% (Spe) |
| Male 55% or more N = 13 |
0.81 (0.77–0.84) | 0.75 (0.67–0.81) | 0.74 (0.67–0.80) | 8 (5–13) | 66.4% (Sen) 78.8% (Spe) |
| Age less than 50 N = 8 |
0.70 (0.65–0.74) | 0.75 (0.66–0.82) | 0.71 (0.67–0.75) | 7 (4–11) |
34.4% (Sen) 81.8% (Spe) |
| Age more than 50 N = 14 |
0.76 (0.67–0.83) | 0.74 (0.69–0.83) | 0.80 (0.77–0.84) | 9 (6–14) | 84.4% (Sen) 68.8% (Spe) |
| Outside China N = 9 |
0.70 (0.63–0.76) | 0.68 (0.64–0.73) | 0.75 (0.71–0.78) | 5 (4–7) |
51.4% (Sen) 62.8% (Spe) |
| China N = 15 |
0.77 (0.70–0.83) | 0.78 (0.73–0.82) | 0.84 (0.81–0.87) | 12 (9–17) | 83.4% (Sen) 73.8% (Spe) |